ProShares Ultra Semiconductors (USD) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Leveraged / InverseSector
- $113.5352W High
- $40.9752W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track ProShares Ultra Semiconductors (USD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ProShares Ultra Semiconductors has traded between a low of $40.97 and a high of $113.53, highlighting its annual price range. Buy and sell ProShares Ultra Semiconductors shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Most Recent News
Director Carande buys 2,101 shares of United Community Banks, signaling confidence.
Director Carande has purchased 2,101 shares of United Community Banks. This insider buying may indicate confidence in the company's future prospects. Investors often view such transactions as a positive signal, potentially influencing market sentimen...
IBM advances quantum computing; Target beats Q2 expectations; Treasury doubles bond buybacks; Amazon expands drone delivery.
IBM achieved a key milestone by linking and cooling two cryogenic modules, moving closer to a fault-tolerant quantum computer with plans for 1,000 qubits next year. Target reported strong Q2 results, surpassing earnings and sales expectations despite...
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027
Jade Biosciences is developing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), aiming for quarterly dosing to improve patient adherence compared to competitors. Phase 1 data show JADE101 reduces IgA levels by about 70% with a good sa...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.